Under construction – not a live service
Sign in
Enrolling by invitationPhase 2

Scan Tests Whether a PET Imaging Agent Detects Kidney Cancer Before Surgery

Tests a PET scan with 68Ga-NYM096 in adults with kidney masses before surgery.

Key facts

Who runs it
Peking Union Medical College Hospital
Where
Beijing, ChinaSee the site
Trial code
Registry title
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Status
Enrolling by invitation
Phase
Phase 2
People taking part
100 people, planned
Started
1 Jul 2025
Expected to end
1 Jul 2027
Type of study
Interventional
Treatments tested
  • 68Ga-NYM096 PET/CT
Record updated
8 August 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a kidney mass who are scheduled for surgery to remove it. A 68Ga-NYM096 PET/CT scan is tested for finding clear cell kidney cancer.

Age
18 years or older
Sex
All sexes can join
Disease stage
A kidney mass (one or several) with a largest diameter of at least 1 cm (0.4 in), seen on standard imaging. Surgery to remove the mass is planned within 1 month.

Main reasons for not taking part

  • High anesthesia risk (ASA class IV or higher) or severe heart or lung problems
  • Active bleeding or blood clotting problems
  • Pregnant or breastfeeding women
  • Claustrophobia, weight over 150 kg (331 lb), or alcohol allergy
  • Any condition the investigator thinks could affect the results or add risk

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age: ≥18 years
  • Gender: No restriction
  • Renal mass (solitary or multiple) with a maximum diameter ≥1 cm, confirmed by conventional imaging (ultrasound, non-contrast CT, contrast-enhanced CT, or MRI)
  • Scheduled for renal mass resection (partial or total nephrectomy, via open, laparoscopic, or robot-assisted techniques) within 1 month
  • Life Expectancy:; At least 3 months, as assessed by a clinician; ECOG Performance Status: 0-2
  • Informed Consent: Provision of written informed consent
  • Compliance: Willing and able to adhere to study procedures

Who cannot take part

  • Other Contraindications:; Claustrophobia; Weight >150 kg ; Alcohol allergy
  • Any condition deemed by the investigator to interfere with study results or increase participant risk
  • Surgical Contraindications:; High anesthesia risk (ASA class ≥IV); Severe cardiopulmonary dysfunction (NYHA class III-IV or FEV1 <50%); Active bleeding or coagulation disorders (INR >1.5, platelets <80×10⁹/L)
  • Pregnancy/Lactation:; Pregnant (positive blood/urine HCG) or breastfeeding women; childbearing potential without effective contraception

Where in China

  • Peking Union Medical College HospitalBeijing, ChinaNo longer taking part

About the trial

What the trial wants to find out

This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients who have renal masses scheduled for surgical resection. The goal is to determine the sensitivity and specificity of 68Ga-NYM096 PET/CT in the detection of clear cell renal cell carcinoma using histopathological diagnosis as ground truth, in patients with operable renal masses.

The group in the trial

  • 68Ga-NYM096 PET/CTTreatment being tested

    Each patient will receive one dose of 68Ga-NYM096 by intravenous route. Dedicated whole-body PET/CT imaging will be performed.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
68Ga-NYM096 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
Plain-language title
Scan Tests Whether a PET Imaging Agent Detects Kidney Cancer Before SurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
8 August 2025